Medicamen Biotec
NSE: MEDICAMEQ · Pharmaceuticals
Snapshot
Unlock Medicamen Biotec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medicamen Biotech Limited is an Indian pharmaceutical company engaged in the manufacturing and distribution of diverse formulations. Its product portfolio includes tablets, capsules, syrups, ointments, and specialised dental care solutions.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations across various therapeutic categories. It operates as a manufacturer catering to both domestic and potentially international markets.
- Incorporation Year:1993
Growth Outlook
Growth is expected to be driven by the expansion of its product range and the increasing demand for affordable pharmaceutical formulations in the Indian market.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and profit margins.
- Raw Material Costs. Fluctuations in the prices of active pharmaceutical ingredients and excipients can adversely impact the company's operating margins.
Start your research today
Unlock AI insights, financials, peers and live data on Medicamen Biotec and 5,000+ companies — free.
Key Metrics
REVENUE
₹203 Cr
TTM · consolidated
NET PROFIT
₹10 Cr
TTM · consolidated
EPS
₹7.41
TTM · consolidated
RETURN ON EQUITY
4.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.2%
TTM · consolidated
P/E
36.5x
Q1 FY27 · consolidated
EV/EBITDA
16.8x
Q1 FY27 · consolidated
EBITDA MARGIN
11.3%
TTM · consolidated
NET PROFIT MARGIN
3.9%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Medicamen BiotecMEDICAMEQ | ₹367 Cr | 36.47 | 16.80 | 24.7% | 11.3% | 4.1% | 6.2% | -22.0% |
Valiant Laboratories LimitedVALIANTLAB | ₹576 Cr | -203.79 | 70.67 | 78.0% | 3.7% | -1.3% | 0.8% | +23.2% |
Albert DavidALBERTDAVD | ₹491 Cr | 21.76 | 12.93 | 11.4% | 11.0% | 5.8% | 7.5% | +7.6% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹458 Cr | 13.20 | 8.38 | — | 32.0% | 17.6% | 23.2% | -10.7% |
TranschemTRANSCHEM | ₹439 Cr | 102.28 | 70.76 | -100.0% | 177.7% | 5.3% | 7.0% | +610.3% |
Haleos Labs LimitedHALEOSLABS | ₹439 Cr | 27.77 | 12.42 | -3.1% | 13.6% | 7.4% | 10.3% | — |
As of Q1 FY27
Financials
Medicamen Biotec
NSE: MEDICAMEQ · Pharmaceuticals
Snapshot
Unlock Medicamen Biotec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medicamen Biotech Limited is an Indian pharmaceutical company engaged in the manufacturing and distribution of diverse formulations. Its product portfolio includes tablets, capsules, syrups, ointments, and specialised dental care solutions.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations across various therapeutic categories. It operates as a manufacturer catering to both domestic and potentially international markets.
- Incorporation Year:1993
Growth Outlook
Growth is expected to be driven by the expansion of its product range and the increasing demand for affordable pharmaceutical formulations in the Indian market.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and profit margins.
- Raw Material Costs. Fluctuations in the prices of active pharmaceutical ingredients and excipients can adversely impact the company's operating margins.
Start your research today
Unlock AI insights, financials, peers and live data on Medicamen Biotec and 5,000+ companies — free.
Key Metrics
REVENUE
₹203 Cr
TTM · consolidated
NET PROFIT
₹10 Cr
TTM · consolidated
EPS
₹7.41
TTM · consolidated
RETURN ON EQUITY
4.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.2%
TTM · consolidated
P/E
36.5x
Q1 FY27 · consolidated
EV/EBITDA
16.8x
Q1 FY27 · consolidated
EBITDA MARGIN
11.3%
TTM · consolidated
NET PROFIT MARGIN
3.9%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27